StockNews.AI
XLO
StockNews.AI
197 days

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1. Xilio granted 83,400 stock options to new employees, effective Feb 1, 2025. 2. Options have an exercise price of $0.705, matching Jan 31 closing price. 3. Stock options will vest over four years, enhancing employee retention. 4. Xilio focuses on tumor-activated immuno-oncology therapies for cancer treatment.

4m saved
Insight
Article

FAQ

Why Neutral?

The stock option grant shows stability but isn't a direct growth signal. Previous stock option grants have had minimal direct impact on share prices.

How important is it?

Employee retention strategies are important but do not directly influence financial metrics. Previous similar practices had a neutral effect on stock price.

Why Short Term?

The immediate effect stems from employee onboarding, but long-term impact is unclear. Past similar events showed fleeting short-term reactions.

Related Companies

XLO
February 03, 2025 16:30 ET  | Source: Xilio Therapeutics, Inc. WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective February 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 83,400 shares of its common stock to four new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.705 per share, which is equal to the closing price of the company’s common stock on January 31, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grants and were made as an inducement material to each individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). About Xilio TherapeuticsXilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.). This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Investor and Media Contact: Scott YoungVice President, Investor Relations and Corporate Communicationsinvestors@xiliotx.com

Related News